Fig. 7

Gö6976 rescues phosphorylation signals and phenotypes in PGRN-KI mice. a Experimental protocol for PKC inhibitor (Gö6976). Gö6976 (4.4 μM) or PBS was injected via osmotic pump into the subarachnoid space of PGRN-KI and C57BL/6J mice from 10 to 12 weeks of age, and behavioral tests and western blots were performed at 12 weeks. b In vivo effect of Gö6976 on PKCα in cortical tissues of PGRN-KI mice. ^##p < 0.01 (N = 6, Tukey’s HSD test). Averages and s.e.m. are shown. c In vivo effect of Gö6976 on phosphorylation of tau in cortical tissues of PGRN-KI mice. Right panels show quantitation of western blot band intensities. ^##p < 0.01 (N = 6, Tukey’s HSD test). Averages and s.e.m. are shown. d In vivo effect of Gö6976 on two parameters (% time spent at target region and number of target crosses) in Morris water maze test. p-values were determined by Student’s t-test (N = 10). Averages and s.e.m. are shown. e Effect of Gö6976 on % total freezing time in the fear-conditioning test. p-values were determined by Student’s t-test (N = 9). Averages and s.e.m. are shown. p-values are shown in Supplementary Data 1